VIDA Mobile Health Cardiovascular Prevention Program

This is a single-center, randomized trial designed to examine the hypothesis that a lifestyle-based mobile health cardiovascular disease (CVD) prevention program administered to graduates of a cardiac rehabilitation (CR) program will improve physical activity, body composition, fitness, and quality of life (QOL).

The investigators may enroll up to 52 men and women volunteers from a pool of graduates of the Duke Cardiac Rehabilitation Program who are initially eligible to participate in this study. Of the 52 men and women volunteers who may be initially consented, it is anticipated that a portion (potentially 30%) may drop out during the study timeline, and approximately 40 are expected to complete this study. Following informed consent and baseline testing, the participants will be randomized in a 3:1 fashion to receive VIDA's 12-week mHealth program focused on lifestyle modification through remote health coaching in order to improve physical activity, body composition, and fitness. The multi-domain mHealth intervention will mirror traditional CR programs by focusing primarily on a structured physical activity intervention within the context of a comprehensive lifestyle program. Physical activity will be monitored by Fitbits and will be integrated into VIDA's mHealth platform which will also include modules on physical activity, weight management, heart healthy diet, medication adherence, coping with a chronic disease, psychosocial management, and stress management/sleep. Health coaches will be used to guide patients through the 12-week program. All participants will undergo measures of physical activity, body composition, fitness, and QOL at baseline and at 12-weeks.

Inclusion criteria

• Graduates of CR, who were originally enrolled in CR following myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) or with stable angina
• Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention
• Ability to participate in a mobile health program with access to smartphones utilizing Apple and Android platforms
• Signed informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study

Exclusion criteria

• Acute symptoms of coronary artery disease
• Decompensated heart failure
• Severe valvular heart disease
• Severe pulmonary hypertension
• End stage renal disease
• Heart failure, New York Heart Association (NYHA) class IV
• Cardiac transplantation
• Terminal illness with life expectancy < 1 year
• Impairment from stroke, injury or other medical disorder that precludes participation in the intervention
• Dementia that precludes ability to participate in and follow study protocols
• Enrollment in a clinical trial not approved for co-enrollment
• Inability or unwillingness to comply with the study requirements